Key Points
- BeOne Medicines CEO John Oyler sold 1,949 shares on June 11 at an average price of $257.24, totaling about $501,361. The filing says the sale was to cover tax withholding obligations tied to vesting equity awards.
- Oyler also sold 4,940 shares on June 8 at an average price of $270.56, indicating additional recent insider selling activity.
- Despite the insider sales, Wall Street remains fairly constructive on NASDAQ:ONC: analysts have a consensus Moderate Buy rating with a $390.00 price target, while the stock recently traded at $268.20.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Titus Ball sold 169 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $257.20, for a total value of $43,466.80. Following the completion of the transaction, the insider directly owned 99,645 shares of the company's stock, valued at $25,628,694. This represents a 0.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
BeOne Medicines Stock Performance
BeOne Medicines stock opened at $268.20 on Tuesday. The business has a 50 day moving average of $298.56 and a 200-day moving average of $314.03. BeOne Medicines Ltd. - Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market capitalization of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion during the quarter. On average, equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 6.14 earnings per share for the current year.
Analyst Ratings Changes
ONC has been the subject of several recent research reports. Leerink Partners upped their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an "outperform" rating in a research note on Friday, May 15th. Morgan Stanley reissued an "overweight" rating and set a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Wolfe Research assumed coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an "outperform" rating and a $340.00 target price for the company. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an "outperform" rating in a research report on Tuesday, June 2nd. Finally, Truist Financial reissued a "buy" rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $390.00.
Read Our Latest Report on BeOne Medicines
Institutional Trading of BeOne Medicines
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONC. EFG International AG acquired a new stake in BeOne Medicines during the 4th quarter valued at approximately $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $35,000. CWM LLC grew its position in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines during the 4th quarter worth approximately $61,000. Institutional investors and hedge funds own 48.55% of the company's stock.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
